Please assess the completion status of the following clinical trial:

Trial Title: Antineoplaston Therapy in Treating Children With Primary Malignant Brain Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed incurable primary malignant brain tumor that has progressed, recurred, or persisted after initial therapy (must have failed standard therapy).~* Evidence of residual tumor by MRI performed within two weeks prior to study entry~PATIENT CHARACTERISTICS:~Age:~* 6 months to 17 years~Performance status:~* Karnofsky 60-100%~Life expectancy:~* At least 2 months~Hematopoietic:~* WBC at least 1,500/mm\^3~* Platelet count greater than 50,000/mm\^3~Hepatic:~* No hepatic failure~* Bilirubin no greater than 2.5 mg/dL~* SGOT/SGPT no greater than 5 times upper limit of normal~Renal:~* Creatinine no greater than 2.5 mg/dL~Cardiovascular:~* No severe heart disease~* No uncontrolled hypertension~Pulmonary:~* No severe lung disease~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception during and for 4 weeks after study participation~* No serious active infections or fever~* No other serious concurrent disease~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* At least 4 weeks since prior immunotherapy and recovered~* No concurrent immunomodulating agents~Chemotherapy:~* At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered~* No concurrent antineoplastic agents~Endocrine therapy:~* Recovered from prior endocrine therapy~* Concurrent corticosteroids for cerebral edema allowed~Radiotherapy:~* At least 8 weeks since prior radiotherapy (unless clear radiological evidence of progression) and recovered~Surgery:~* At least 4 weeks since prior surgery (unless clear radiological evidence of progression) and recovered~Other:~* No prior antineoplaston therapy

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Antineoplaston therapy (Type: EXPERIMENTAL): Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.

Based on this trial design, predict the completion outcome and termination type (if applicable).